Hemoperfusion in Critical Patients With Septic Multiorgan Dysfunction Syndrome.
Key facts
- Who runs it
- Hospital Clinic of Barcelona
- Where
- Spain1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Recruiting
- People taking part
- 48 people, planned
- Started
- 1 Mar 2023
- Planned end
- 20 Dec 2025
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Extracorporeal support with haemoperfusion
- Conventional treatment
- Record updated
- 10 June 2025
Who can take part
- Age
- 18 years to 80 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 17 criteriaShow less
Who can take part
- Patients with a sepsis diagnosis, according to the diagnostic criteria of the International Sepsis-3 Consensus Conference, and without response to the treatment of septic shock who meet the following conditions:
- Sepsis of abdominal origin with controlled infectious focus
- Noradrenaline dose> 0.5 µg / kg / min to maintain adequate organ perfusion after optimization of fluid therapy
- Dysfunction of two or more organs with SOFA ≥ 9 (5)
- Blood lactate ≥ 2 mmol / L
- Procalcitonin (PCT)> 10 ng / mL
- CRP> 100 mg / L
- IL-6> 2000 pg / ml
Who cannot take part
- Severe coagulopathy with high risk of bleeding
- Age under 18 years or over 80 years
- Pregnancy or breastfeeding
- Terminally ill patients or with a life expectancy of less than 48 hours
- Thrombocytopenia <60,000 / mm3
- Pancytopenia
- Inclusion in another research protocol
- In case of re-entry during the study period, only the first admission will be included
- Use of another haemoperfusion device
The main criteria, as questions
These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Are you between 18 and 80 years old?
This trial is currently available in Spain.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Low-level interventional clinical trial to evaluate the effectiveness and safety of extracorporeal support with hemoperfusion in critical patients with septic multiorgan dysfunction syndrome.
The 2 groups in the trial
- Conventional treatmentExisting treatment, for comparison
Patients receiving conventional treatment for multiorganic dysfunction syndrome from septic origin.
- Extracorporeal support with haemoperfusion treatmentTreatment being tested
Patients receiving extracorporeal support with haemoperfusion for multiorganic dysfunction syndrome from septic origin.
Treatment: Extracorporeal support with haemoperfusion
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Clinical Impact of Hemoperfusion With a Neutral Macroporous Resin Cartridge as Adjunctive Treatment in Septic Patients With Multiorgan Dysfunction Syndrome (MODS) Admitted to Intensive Care Units.
- Criteria questions
- Built from NCT05044403, who can take part
- Record updated
- 10 June 2025